Inventiva(NASDAQ) IVA

Market Cap€1.13B

Since IPO (2020)-64%

5 Year-57%

1 Year+32%

1 Month+9%

€4.75

-1.15%

-0.06Today

After hours€4.77+€0.03 (+0.53%)

Inventiva last closing stock price
Metric	Price	Date
Last close	USD 4.80	2026-08-07

Inventiva stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+7.14%	USD 4.48	2026-07-31
1 month	+9.34%	USD 4.39	2026-07-08
3 month	-10.61%	USD 5.37	2026-05-08
Year to date	+3.23%	USD 4.65	2025-12-31
1 year	+31.87%	USD 3.64	2025-08-07
3 year	+24.03%	USD 3.87	2023-08-08
5 year	-57.18%	USD 11.21	2021-08-06
Since inception	-64.23%	USD 13.42	2020-07-10

Inventiva Financials at a Glance

Market Cap

€1.13B

Revenue (TTM)

€13.68M

Net Income (TTM)

-€537.03M

EPS (TTM)

-€2.84

P/E Ratio

-1.69

Dividend

€0.00

Beta (Volatility)

0.41 (Low)

Dividend

€0.00

Beta (Volatility)

0.41 (Low)

Price

€4.75

Volume

443,667

Open

€4.81

Price

€4.75

Volume

443,667

Open

€4.81

Previous Close

€4.75

Daily Range

€4.69 - €4.88

52-Week Range

€3.35 - €7.98

Estimated Earnings Date

Sep 25, 2026

Dividend

€0.00

Beta (Volatility)

0.41 (Low)

Price

€4.75

Volume

443,667

Open

€4.81

Previous Close

€4.75

Daily Range

€4.69 - €4.88

52-Week Range

€3.35 - €7.98

Estimated Earnings Date

Sep 25, 2026

IVA News

No articles available.

IVA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Inventiva

Inventiva S.A. is a biopharmaceutical company focused on designing and developing small molecule therapies. Its primary aim is to address significant unmet medical needs in areas such as fibrosis and oncology. The company utilizes its proprietary NATIVE platform for efficient drug discovery. Inventiva's development pipeline includes treatments for non-alcoholic steatohepatitis (NASH) and systemic sclerosis. The company is well-regarded for its partnerships and collaborations that enhance its research and development capabilities.

Products and Services

Orally-administered small molecule therapies for fibrosis

Therapies targeting oncology

Drug development pipeline for non-alcoholic steatohepatitis (NASH)

Treatments for systemic sclerosis

What Makes Inventiva S.A. Special

Inventiva S.A. differentiates itself with its NATIVE platform, enabling efficient discovery of novel molecules. This technology advances its drug development capabilities, combined with strategic industry partnerships that accelerate its path to commercialization.

Five Things You Need to Know

Inventiva focuses on fibrosis and oncology treatments, areas with significant medical need.

Its NATIVE platform is proprietary and aids in novel molecule discovery.

The development pipeline targets conditions like NASH and systemic sclerosis.

Inventiva is driven by a leadership team with extensive pharmaceutical industry experience.

Strategic partnerships enhance Inventiva's research and development and support accelerated commercialization efforts.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Andrew Obenshain, MBA

Website

www.inventivapharma.com

Headquarters

Daix, BF 21121, FR

IVA Financials

Key Financial Metrics (TTM)

Gross Margin

35.07%

Operating Margin

-3037.30%

Net Income Margin

-7899.58%

Return on Equity

1870.38%

Return on Capital

-431.28%

Return on Assets

-141.93%

Earnings Yield

-59.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

€1.13B

Shares Outstanding

236.24M

Volume

443.67K

Avg. Volume

990.78K

Financials (TTM)

Gross Profit

€10.78M

Operating Income

-€228.50M

EBITDA

-€410.10M

Operating Cash Flow

-€194.08M

Capital Expenditure

-€582.19K

Free Cash Flow

-€194.66M

Cash & ST Invst.

€99.27M

Total Debt

€59.40M

Inventiva Performance Analysis

Inventiva annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 12,799,816	158.2%
2023	2023-12-31	EUR 18,894,657	47.6%
2024	2024-12-31	EUR 9,949,392	-47.3%
2025	2025-12-31	EUR 5,059,415	-49.1%

Inventiva sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	-83.5%
Q4	2024-12-31	136.4%
Q2	2025-06-30	-31.1%
Q4	2025-12-31	-99.4%

Inventiva annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -1.38	-8.1%
2023	2023-12-31	EUR -2.63	91.3%
2024	2024-12-31	EUR -3.33	26.6%
2025	2025-12-31	EUR -2.14	-35.8%

Inventiva sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	16.8%
Q4	2024-12-31	-176.6%
Q2	2025-06-30	37.7%
Q4	2025-12-31	82.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

€28.79K

-99.8%

Gross Profit

-€1.17M

-107.3%

Gross Margin

-40.62%

N/A

Market Cap

€1.13B

N/A

Market Cap/Employee

€15.53M

N/A

Employees

N/A

Net Income

-€176.94M

-220.8%

EBITDA

-€77.74M

-68.1%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

€99.27M

+263.1%

Total Debt

€59.40M

+58.4%

Accounts Receivable

€9.12M

-42.0%

Inventory

€0.00

-100.0%

Long Term Debt

€27.54M

-14.4%

Short Term Debt

€32.31M

+508.7%

Return on Assets

-1.42%

N/A

Return on Invested Capital

-79.10%

N/A

Free Cash Flow

-€54.45M

-48.4%

Operating Cash Flow

-€54.26M

-49.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AVTXAvalo Therapeutics, Inc.

AVTXAvalo Therapeutics, Inc.$19.77+7.91%

GNFTGenfit S.A.

GNFTGenfit S.A.$8.95+4.07%

ENTAEnanta Pharmaceuticals, Inc.

ENTAEnanta Pharmaceuticals, Inc.$13.81+0.29%

OBIOOrchestra BioMed Holdings, Inc.

OBIOOrchestra BioMed Holdings, Inc.$4.46+5.19%

RNACCartesian Therapeutics, Inc.

RNACCartesian Therapeutics, Inc.$8.76-1.02%

EPRXEupraxia Pharmaceuticals Inc.

EPRXEupraxia Pharmaceuticals Inc.$6.66-1.62%

IVVDInvivyd, Inc.

IVVDInvivyd, Inc.$0.67-9.04%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$138.74+0.04%

ACHRArcher Aviation

ACHRArcher Aviation$6.26+0.12%

NVDANvidia

NVDANvidia$217.55-0.03%

INTCIntel

INTCIntel$97.52-0.04%

ONDSOndas

ONDSOndas$9.31+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.21+0.01%

RIGTransocean

RIGTransocean$5.72+0.09%

Questions About IVA

What is the current price of Inventiva?

Inventiva is trading at €4.75 per share.

What is the 52-week range for Inventiva?

Over the past 52 weeks, Inventiva has traded between €3.35 and €7.98.

How much debt does Inventiva have?

As of the most recent reporting period, Inventiva reported total debt of €69.79M.

How much cash does Inventiva have on hand?

Inventiva reported €116.64M in cash and cash equivalents in its most recent financial results.

What is Inventiva’s dividend yield?

Inventiva does not currently have a dividend yield.

Inventiva(NASDAQ) IVA

Inventiva Financials at a Glance

IVA News

IVA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Inventiva

Products and Services

What Makes Inventiva S.A. Special

Five Things You Need to Know

IVA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Inventiva Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IVA

What is the current price of Inventiva?

What is the 52-week range for Inventiva?

How much debt does Inventiva have?

How much cash does Inventiva have on hand?

What is Inventiva’s dividend yield?

Premium Investing Services